Protagonist Therapeutics, Inc. Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.

PTGX

Hisse Senetlerindeki Sıralama #2295
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Hisse Fiyatı
$134.37
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$8.70B
Değişim (1 gün)
4.37%
Değişim (1 yıl)
75.15%
Ülke
US
Ticaret Protagonist Therapeutics, Inc. (PTGX)

Kategori

Healthcare
Protagonist Therapeutics, Inc. (PTGX) için temettü verimi geçmişi
Protagonist Therapeutics, Inc. (hisse sembolü: PTGX) temettü verimi (TTM) 2023-12-31 itibariyle: 0.00%
Son 5 yılın ortalama temettü verimi: 0.00%
Protagonist Therapeutics, Inc. (PTGX) için 2014 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
Yıl Temettü Verimi Değiştir
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
Benzer şirketler veya rakiplerin temettü verimi (TTM)
Şirket Temettü Verimi Ülke
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL